When the mRNA COVID-19 vaccines were initially authorized, they were recommended to be given intramuscularly (IM) in a two-dose series. Doses of the Pfizer-BioNTech vaccine were recommended to be administered 21 days apart, while doses of the Moderna vaccine were to be given 28 days apart. In early January 2021, following reports in the media of alternative vaccine schedules which included giving a single vaccine dose, giving half doses, and using vaccine brands interchangeably, the FDA issued a press release to emphasize the need for clinicians to follow the authorized EUA dosing schedules. Agency officials reported that without clinical data to support alternative dosing schedules, the public could be put at risk and this might ultimately undermine efforts to protect people against COVID-19.
In contrast, U.K. health officials announced in early January 2021 that it was prioritizing first dose administration to as many people as possible, and delaying the booster dose until more vaccines became available.
Studies on the use of different combinations of COVID-19 vaccines were initiated by the University of Oxford and included the evaluation of the safety and effectiveness of using a different COVID-19 vaccine as the second vaccine dose. Vaccines involved in the clinical trials included Pfizer-BioNTech, Moderna, AstraZeneca, and Novavax.
According to a study published in The Lancet on May 12, 2021, adults 50 years and older who received a mixed dose combination of the Pfizer-BioNTech vaccine and the AstraZeneca COVID-19 vaccine experienced more mild and moderate side effects than those administered only one type of vaccine. Systemic reactions, especially fever, were significantly higher after the second vaccine dose in persons who received the AstraZeneca vaccine followed by a dose of the Pfizer-BioNTech vaccine when compared to persons who received two doses of the Pfizer-BioNTech vaccine. There were also more reports of joint and muscle pain, chills, malaise, fatigue, and headache after the second vaccine dose in person who received a mixed dose schedule.
On October 20, 2021, the FDA authorized use of a “mix and match” booster dose for all available COVID-19 vaccines. According to the FDA, the known and potential benefits of a single boost of a different vaccine outweighed the known and potential risks. At the time of this recommendation, there was limited safety and effectiveness data to support the mixed-use vaccine schedule.